169 related articles for article (PubMed ID: 37254147)
1. miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Gonzalez-Martinez A; Patel R; Healy BC; Lokhande H; Paul A; Saxena S; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 May; 20(1):131. PubMed ID: 37254147
[TBL] [Abstract][Full Text] [Related]
2. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
3. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
Dominguez-Mozo MI; Galán V; Ramió-Torrentà L; Quiroga A; Quintana E; Villar LM; Costa-Frossard L; Fernández-Velasco JI; Villarrubia N; Garcia-Martinez MA; Arroyo R; Alvarez-Lafuente R
Front Immunol; 2024; 15():1384411. PubMed ID: 38911861
[TBL] [Abstract][Full Text] [Related]
4. Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Saab G; Shah P
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224046
[TBL] [Abstract][Full Text] [Related]
5. Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod.
Mazdeh M; Kordestani H; Komaki A; Eftekharian MM; Arsang-Jang S; Branicki W; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2020 Aug; 70(8):1274-1281. PubMed ID: 32215780
[TBL] [Abstract][Full Text] [Related]
6. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
Guerra T; Caputo F; Orlando B; Paolicelli D; Trojano M; Iaffaldano P
Neurol Sci; 2021 Nov; 42(11):4647-4655. PubMed ID: 33677753
[TBL] [Abstract][Full Text] [Related]
7. Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study.
Gonzalez-Martinez A; Bose G; Lokhande H; Saxena S; Healy BC; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 Jun; 20(1):136. PubMed ID: 37264432
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
Fissolo N; Pappolla A; Rio J; Villar LM; Perez-Hoyos S; Sanchez A; Gutierrez L; Montalban X; Comabella M
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411079
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
11. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
12. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.
Casanova I; Domínguez-Mozo MI; De Torres L; Aladro-Benito Y; García-Martínez Á; Gómez P; Abellán S; De Antonio E; Álvarez-Lafuente R
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893133
[TBL] [Abstract][Full Text] [Related]
15. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
Fenoglio C; De Riz M; Pietroboni AM; Calvi A; Serpente M; Cioffi SM; Arcaro M; Oldoni E; Scarpini E; Galimberti D
J Neuroimmunol; 2016 Oct; 299():81-83. PubMed ID: 27725128
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in multiple sclerosis patients treated with fingolimod.
Lattanzi S; Rocchi C; Danni M; Taffi R; Cerqua R; Carletti S; Silvestrini M
Mult Scler Relat Disord; 2020 Oct; 45():102416. PubMed ID: 32721897
[TBL] [Abstract][Full Text] [Related]
17. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
